The standard 3.2 mg KLOW dose contains 2 mg GHK-Cu and 400 mcg each of BPC-157, TB-4, and KPV
Practical Concerns Product quality: The most significant real-world risk with BPC-157 today is source quality
The treatment involves drawing a blood sample, processing it to concentrate the platelets, and injecting the platelet-rich plasma into the affected joint
Krivic et al., 2008)
Statements regarding dietary supplements, including peptides such as BPC-157, have not been evaluated by the Food and Drug Administration (FDA)
Explore Use this educational Retatrutide units calculator and dose escalation chart to better understand how dose, concentration, mL, syringe units, and vial size may work together